View Older Stories View More Recent Stories

Nov 22, 2024 06:46AM Merck's (MRK) WELIREG Approved in China for Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
Nov 22, 2024 06:45AM Merck’s WELIREG® (belzutifan) Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
Nov 22, 2024 06:34AM Merck (MRK) Announces Surendralal Karsanbhai Elected to Board of Directors
Nov 22, 2024 06:30AM Surendralal Karsanbhai Elected to Merck Board of Directors
Nov 21, 2024 06:45AM Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities
Nov 19, 2024 12:22PM Merck Announces First-Quarter 2025 Dividend
Nov 19, 2024 06:45AM Merck (MRK) Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
Nov 19, 2024 06:45AM Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
Nov 15, 2024 07:16AM Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA Plus Chemo as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid MPM
Nov 15, 2024 07:15AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Non-Epithelioid Malignant Pleural Mesothelioma (MP
Nov 14, 2024 07:15AM Merck to Participate in the Jefferies London Healthcare Conference
Nov 14, 2024 06:45AM Merck (MRK) Enters into Exclusive Global License for LM-299
Nov 14, 2024 06:45AM Merck Enters into Exclusive Global License for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody from LaNova Medicines Ltd.
Nov 12, 2024 06:45AM Merck (MRK) reports KOSELUGO Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo
Nov 12, 2024 06:45AM KOSELUGO® (selumetinib) Showed Significant and Clinically Meaningful Improvement in Objective Response Rate Versus Placebo in Adults With Neurofibromatosis Type 1 who Have Symptomatic, Inoperable Ple
Nov 12, 2024 03:00AM Merck to Present New Data From GARDASIL®9 Studies Reinforcing the Importance of Gender-Neutral HPV Vaccination in Adults Up to Age 45 at the International Papillomavirus Conference (IPVC) 2024
Nov 6, 2024 06:45AM Merck to Participate in the UBS Global Healthcare Conference
Oct 31, 2024 06:30AM Merck Announces Third-Quarter 2024 Financial Results
Oct 29, 2024 08:01AM MilliporeSigma Invests $76 Million to Expand ADC Manufacturing for Novel Cancer Therapies
Oct 28, 2024 06:46AM Merck (MRK) and Moderna (MRNA) Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA
Oct 28, 2024 06:45AM Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types
Oct 24, 2024 06:45AM Merck's (MRK) KEYTRUDA Receives 30th Approval From EU Commission With Two New Indications in Gynecologic Cancers
Oct 24, 2024 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers
Oct 23, 2024 07:58PM CDC’S ACIP Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older
Oct 21, 2024 05:59AM Gilead Sciences (GILD) and Merck (MRK) Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppre
Oct 21, 2024 05:58AM Gilead Sciences (GILD) and Merck (MRK) Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppre
Oct 19, 2024 05:09PM Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Wee
Oct 18, 2024 05:50AM Merck's (MRK) MK-1654 Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants
Oct 17, 2024 06:00PM Merck’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Pr
Oct 16, 2024 06:45AM Merck's (MRK) CAPVAXIVE Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease
Oct 16, 2024 06:45AM Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease
Oct 14, 2024 08:02AM Exelixis (EXEL) and Merck (MRK) Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA
Oct 14, 2024 08:00AM Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELI
Oct 9, 2024 08:01AM MilliporeSigma Opens New €290 Million Biosafety Testing Facility in Rockville, Maryland, USA
Oct 9, 2024 06:45AM New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and Portfolio
Oct 8, 2024 06:45AM Merck's (MRK) KEYTRUDA Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma
Oct 8, 2024 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcin
Oct 1, 2024 06:46AM Merck (MRK) Completes Acquisition of CN201 from Curon Biopharmaceutical
Oct 1, 2024 06:45AM Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
Oct 1, 2024 06:30AM Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31
Sep 26, 2024 06:46AM Merck (MRK) to Present New Long-Term Data for Tulisokibart
Sep 26, 2024 06:45AM Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024
Sep 25, 2024 06:45AM Merck (MRK) Provides Update on Phase 3 KEYFORM-007 Trial of Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab
Sep 25, 2024 06:45AM Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite
Sep 25, 2024 06:30AM Merck's (MRK) KEYTRUDA Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma
Sep 25, 2024 06:30AM Merck’s KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma
Sep 24, 2024 08:06AM Merck Animal Health (MRK) Announces Expansion of NOBIVAC NXT Platform
Sep 24, 2024 08:06AM Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus
Sep 20, 2024 09:00AM How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
Sep 20, 2024 07:30AM Merck (MRK) Receives Positive EU CHMP Opinions for KEYTRUDA Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
View More Recent Stories View Older Stories